{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:08Z","timestamp":1772166428686,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FIMABIS. Andalusian public foundation for biomedical and health research in M\u00e1laga city.","award":["PI-0059-2016"],"award-info":[{"award-number":["PI-0059-2016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oral anticoagulant drugs represent an essential tool in the prevention of thromboembolic events. The ones in widespread use are vitamin K antagonists, whose plasma level is monitored by measuring prothrombin time using the international normalized ratio. If its values are out of the recommended range, the patient will have a higher risk of suffering from thromboembolic or hemorrhagic complications. Previous research has shown that approximately 33% of patients keep having values at an inappropriate level. The purpose of the proposed study is to improve the international normalized ratio control results by a joint didactic intervention based on the Junta de Andaluc\u00eda School for Patients method that will be implemented by anticoagulated patients themselves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A randomized controlled trial will be undertaken at primary care centers from one healthcare area in M\u00e1laga (Andalusia, Spain). Study population: patients participating in an oral anticoagulant therapy program of vitamin K antagonists.<\/jats:p>\n                    <jats:p>First step: identification of patients in the oral anticoagulation therapy program with international normalized ratio control of the therapeutic level at 65% or less over total time. Second step: patients with international normalized ratio (INR) control figures under 2 or above 3 will be assigned to two different groups:<\/jats:p>\n                    <jats:p>Group 1 or joint intervention group: patients will be instructed in the joint didactic \u201cfrom peer to peer,\u201d by a previously trained and expert anticoagulant patient.<\/jats:p>\n                    <jats:p>Group 2 or control group: the control group will receive the usual clinical practice. They will be evaluated by nurses about once a month, except for cases in which their INR figures are under 2 or above 3, and those patients will be evaluated more frequently.<\/jats:p>\n                    <jats:p>A total of 312 individuals will be required (156 in each group) to detect differences in INR figures equal to or higher than 15% between the groups.<\/jats:p>\n                    <jats:p>Study variables: time on therapeutic levels before and after the intervention; sociodemographic variables; vital signs; the existence of cardiovascular risk factors or accompanying diseases in the clinical records; laboratory test including complete blood counts, bleeding time, and prothrombin time or partial thromboplastin time; and blood chemistry, other prescribed drugs, and social support.<\/jats:p>\n                    <jats:p>A quasi-experimental analytic study with before-after statistical analysis of the intervention will be conducted. Linear regression models will be applied for the main variable results (international normalized ratio value, time on therapeutic level) inputting sociodemographic variables, accompanying diseases, and social support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03647254\">NCT03647254<\/jats:ext-link>\n                      . Registered on 27 August 2018\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-020-04972-1","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T07:19:19Z","timestamp":1610349559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of a joint didactic intervention using the Junta De Andaluc\u00eda School for Patients method to control prothrombin time in patients taking anticoagulants: protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8350-3524","authenticated-orcid":false,"given":"Leovigildo","family":"Ginel-Mendoza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Hidalgo-Natera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Reina-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Poyato-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juana","family":"Morales-Naranjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Lupia\u00f1ez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Baca-Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Guti\u00e9rrez-Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Paz","family":"Fern\u00e1ndez-Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Lozano-Noriega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulises","family":"Salgado-Carvallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bandera-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Navarro-Moya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"issue":"5","key":"4972_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.thromres.2004.11.025","volume":"117","author":"A Od\u00e9n","year":"2006","unstructured":"Od\u00e9n A, Fabl\u00e9n M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res. 2006;117(5):493\u20139.","journal-title":"Thromb Res"},{"issue":"12","key":"4972_CR2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857\u201367.","journal-title":"Ann Intern Med"},{"issue":"2","key":"4972_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","volume":"1","author":"Y Wan","year":"2008","unstructured":"Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovas Qual Outcomes. 2008;1(2):84\u201391.","journal-title":"Circ Cardiovas Qual Outcomes"},{"issue":"4","key":"4972_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12529-012-9242-5","volume":"19","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, Granam I, Reiner Z, Verschurren WMM, et al. European Guidelines on cardiovascular disease prevention in clinical practice: the Fifth Joint Task Forc\u00e9 of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and invited experts). Int J Behav Med. 2012;19(4):403\u201388.","journal-title":"Int J Behav Med"},{"key":"4972_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.recesp.2013.07.015","volume":"67","author":"JJ G\u00f3mez-Doblas","year":"2014","unstructured":"G\u00f3mez-Doblas JJ, Mu\u00f1iz J, Martin JJA, Rodriguez-Roca G, Lobos JM, Awamleh P, et al. Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Espanola Cardiol Engl Ed. 2014;67:259\u201369.","journal-title":"Rev Espanola Cardiol Engl Ed"},{"issue":"11","key":"4972_CR6","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.amjcard.2009.07.022","volume":"104","author":"GV Naccarelli","year":"2009","unstructured":"Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534\u20139.","journal-title":"Am J Cardiol"},{"issue":"2","key":"4972_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372.","journal-title":"Chest"},{"key":"4972_CR8","doi-asserted-by":"publisher","first-page":"d124","DOI":"10.1136\/bmj.d124","volume":"342","author":"JB Olesen","year":"2011","unstructured":"Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.","journal-title":"BMJ"},{"key":"4972_CR9","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369\u2013429.","journal-title":"Eur Heart J"},{"key":"4972_CR10","doi-asserted-by":"publisher","first-page":"g2116","DOI":"10.1136\/bmj.g2116","volume":"348","author":"BA Steinberg","year":"2014","unstructured":"Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ. 2014;348:g2116.","journal-title":"BMJ"},{"issue":"3","key":"4972_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/(SICI)1098-2825(2000)14:3<101::AID-JCLA4>3.0.CO;2-A","volume":"14","author":"RS Riley","year":"2000","unstructured":"Riley RS, Rowe D, Fisher LM. Clinical utilization of the international normalized ratio (INR). J Clin Lab Anal. 2000;14(3):101\u201314.","journal-title":"J Clin Lab Anal"},{"key":"4972_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.medcli.2012.12.023","volume":"141","author":"JM Lobos-Bejarano","year":"2013","unstructured":"Lobos-Bejarano JM, del Castillo-Rodr\u00edguez JC, Mena-Gonz\u00e1lez A, Alem\u00e1n-S\u00e1nchez JJ, Cabrera de Le\u00f3n A, Bar\u00f3n-Esquivias G, et al. Patients\u2019 characteristics and clinical management of atrial fibrillation in primary healthcare in Spain: FIATE Study. Med Clin (Barc). 2013;141:279\u201386.","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"4972_CR13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1160\/TH11-05-0353","volume":"106","author":"AM Gallagher","year":"2011","unstructured":"Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa T-P. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968\u201377.","journal-title":"Thromb Haemost"},{"issue":"1","key":"4972_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jelectrocard.2012.08.011","volume":"46","author":"SY Han","year":"2013","unstructured":"Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, et al. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. J Electrocardiol. 2013;46(1):45\u201350.","journal-title":"J Electrocardiol"},{"key":"4972_CR15","doi-asserted-by":"crossref","unstructured":"Clarkesmith DE, Pattison HM, Khaing PH, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev. 2017; Available: https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008600.pub3\/abstract.","DOI":"10.1002\/14651858.CD008600.pub3"},{"key":"4972_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.recesp.2015.04.017","volume":"68","author":"V Barrios","year":"2015","unstructured":"Barrios V, Escobar C, Prieto L, Osorio G, Polo J, Lobos JM, et al. Anticoagulation control in patients with nonvalgular atrial fibrillation attended at primary care centers in Spain. The PAULA study. Rev Espanola Cardiol Engl Ed. 2015;68:769\u201376.","journal-title":"Rev Espanola Cardiol Engl Ed"},{"key":"4972_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.rec.2015.12.005","volume":"69","author":"S Cinza Sanjurio","year":"2016","unstructured":"Cinza Sanjurio S, Rey Aldana D, Gestal Pereira E, Calvo G\u00f3mez C, ANFAGAL (Anticoagulaci\u00f3n en pacientes con Fibrilaci\u00f3n auricular en \u00e1mbito de atenci\u00f3n primaria de Galicia) study. Degree of anticoagulation control in patients with atrial fibrillation in Spain: need to minimize biases and contextualize results. Response by CInza Sanjurio et al. Rev Espanola Cardiol Engl Ed. 2016;69:357\u20138. https:\/\/doi.org\/10.1016\/j.rec.2015.12.005.","journal-title":"Rev Espanola Cardiol Engl Ed"},{"key":"4972_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.recesp.2014.11.022","volume":"68","author":"M Anguita S\u00e1nchez","year":"2015","unstructured":"Anguita S\u00e1nchez M, Bertomeu Mart\u00ednez V, Cequier Fillat \u00c1, CALIFA study researchers. Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors. Rev Espanola Cardiol Engl Ed. 2015;68:761\u20138.","journal-title":"Rev Espanola Cardiol Engl Ed"},{"issue":"1","key":"4972_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S1134-282X(09)70072-7","volume":"24","author":"J C\u00e1rdenas Valladolid","year":"2009","unstructured":"C\u00e1rdenas Valladolid J, Mena Mateo J, Ca\u00f1ada Dorado MM, Rodriguez Morales D, S\u00e1nchez Perruca L. Implementation and improvement in a care program for the elderly on mulitiple medications in a primary care \u00e1rea. Rev Calid Asist. 2009;24(1):24\u201331.","journal-title":"Rev Calid Asist"},{"key":"4972_CR20","doi-asserted-by":"publisher","unstructured":"Clarkesmith DE, Pattison HM, Lane DA. Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013. https:\/\/doi.org\/10.1002\/14651858.CD008600.pub2.","DOI":"10.1002\/14651858.CD008600.pub2"},{"key":"4972_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.gaceta.2013.01.008","volume":"27","author":"R Nu\u00f1o-Solinis","year":"2013","unstructured":"Nu\u00f1o-Solinis R, Rodr\u00edguez-Pereira C, Pi\u00f1era-Elorriaga K, Zaballa-Gonz\u00e1lez I, Bikandi-Irazabal J. Panorama of self-management initiatives in Spain. Gac Sanit. 2013;27:332\u20137.","journal-title":"Gac Sanit"},{"key":"4972_CR22","doi-asserted-by":"publisher","first-page":"f2614","DOI":"10.1136\/bmj.f2614","volume":"346","author":"T Richards","year":"2013","unstructured":"Richards T, Montori VM, Godlee F, Lapsley P, Paul D. Let the patient revolution begin. BMJ. 2013;346:f2614.","journal-title":"BMJ"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04972-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-04972-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04972-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T07:55:45Z","timestamp":1610351745000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04972-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4972"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04972-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-17348\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"15 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics and Research Committee of Malaga granted the approval for this trial. The regulations on Good Clinical Practice will be observed at all times, as well as the ethical principles established for the research on human beings stipulated in the Declaration of Helsinki and further amendments thereto. The clinical information will remain separate from the identification details, and the databases will be coded and stored in specific computers solely intended for the project. All the records will be made observing all the dispositions from the legislation in force with regard to personal data protection according to the Act 15\/1999 dated 13 December, as well as on safety files which may store personal data information, and more specifically, with regard to the access through communication networks (Royal Decree 994\/1999 dated 11 June) and access to confidential information for scientific purposes from the Commission Regulation CE No. 831\/2002 by the European Union and Act 41\/2002 dated 14 November, which is considered the legal standard on Patient\u2019s Autonomy and Rights and Duties in terms of Clinical Information and Documentation. The staff responsible for such purpose will manage the data according to the instructions provided by the person responsible for the treatment. Such data will not be applied or used for a different purpose than those stated in the respective authorization; neither will they be reproduced to other people even for registration purposes. Once the aim of the trial has been carried out, the personal data collected will be destroyed, deleted, or given back to the person responsible for the treatment, along with any other media or documents containing any personal data related to the project. Every patient will be informed verbally and in writing about the objectives of the project and its methodology. Each individual will sign the respective informed consent form. On the consent form, participants will be asked if they agree to the use of their data should they choose to withdraw from the trial. Participants will also be asked for permission for the research team to share relevant data with people from the Universities taking part in the research or from regulatory authorities, where relevant. This trial involves collecting biological specimens for storage.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors gave their consent to take part in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}